147 related articles for article (PubMed ID: 22130903)
21. EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer.
Ålgars A; Lintunen M; Carpén O; Ristamäki R; Sundström J
Br J Cancer; 2011 Jul; 105(2):255-62. PubMed ID: 21694725
[TBL] [Abstract][Full Text] [Related]
22. Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients.
Liang Z; Zeng X; Gao J; Wu S; Wang P; Shi X; Zhang J; Liu T
BMC Cancer; 2008 Dec; 8():363. PubMed ID: 19061514
[TBL] [Abstract][Full Text] [Related]
23. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.
Sartore-Bianchi A; Moroni M; Veronese S; Carnaghi C; Bajetta E; Luppi G; Sobrero A; Barone C; Cascinu S; Colucci G; Cortesi E; Nichelatti M; Gambacorta M; Siena S
J Clin Oncol; 2007 Aug; 25(22):3238-45. PubMed ID: 17664472
[TBL] [Abstract][Full Text] [Related]
24. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients.
Cappuzzo F; Varella-Garcia M; Finocchiaro G; Skokan M; Gajapathy S; Carnaghi C; Rimassa L; Rossi E; Ligorio C; Di Tommaso L; Holmes AJ; Toschi L; Tallini G; Destro A; Roncalli M; Santoro A; Jänne PA
Br J Cancer; 2008 Jul; 99(1):83-9. PubMed ID: 18577988
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical expression of EGFR in colorectal carcinoma correlates with high but not low level gene amplification, as demonstrated by CISH.
Hemmings C; Broomfield A; Bean E; Whitehead M; Yip D
Pathology; 2009; 41(4):356-60. PubMed ID: 19404848
[TBL] [Abstract][Full Text] [Related]
26. Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.
Scartozzi M; Giampieri R; Maccaroni E; Mandolesi A; Giustini L; Silva R; Zaniboni A; Biscotti T; Biagetti S; Galizia E; Loupakis F; Falcone A; Bearzi I; Cascinu S
Ann Oncol; 2012 Jul; 23(7):1706-12. PubMed ID: 22112971
[TBL] [Abstract][Full Text] [Related]
27. Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines.
Press MF; Seoane JA; Curtis C; Quinaux E; Guzman R; Sauter G; Eiermann W; Mackey JR; Robert N; Pienkowski T; Crown J; Martin M; Valero V; Bee V; Ma Y; Villalobos I; Slamon DJ
JAMA Oncol; 2019 Mar; 5(3):366-375. PubMed ID: 30520947
[TBL] [Abstract][Full Text] [Related]
28. Assessment of mean EGFR gene copy number is a highly reproducible method for evaluating FISH in histological and cytological cancer specimens.
Zlobec I; Raineri I; Schneider S; Schoenegg R; Grilli B; Herzog M; Savic S; Bubendorf L
Lung Cancer; 2010 May; 68(2):192-7. PubMed ID: 19616866
[TBL] [Abstract][Full Text] [Related]
29. EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy.
Thunnissen E; Bovée JV; Bruinsma H; van den Brule AJ; Dinjens W; Heideman DA; Meulemans E; Nederlof P; van Noesel C; Prinsen CF; Scheidel K; van de Ven PM; de Weger R; Schuuring E; Ligtenberg M
J Clin Pathol; 2011 Oct; 64(10):884-92. PubMed ID: 21947301
[TBL] [Abstract][Full Text] [Related]
30. Strong nuclear EGFR expression in colorectal carcinomas is associated with cyclin-D1 but not with gene EGFR amplification.
Dekanić A; Dintinjan RD; Budisavljević I; Pećanić S; Butorac MŽ; Jonjić N
Diagn Pathol; 2011 Nov; 6():108. PubMed ID: 22050898
[TBL] [Abstract][Full Text] [Related]
31. Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number.
Italiano A; Follana P; Caroli FX; Badetti JL; Benchimol D; Garnier G; Gugenheim J; Haudebourg J; Keslair F; Lesbats G; Lledo G; Roussel JF; Pedeutour F; François E
Ann Surg Oncol; 2008 Feb; 15(2):649-54. PubMed ID: 17987340
[TBL] [Abstract][Full Text] [Related]
32. Defining EGFR amplification status for clinical trial inclusion.
French PJ; Eoli M; Sepulveda JM; de Heer I; Kros JM; Walenkamp A; Frenel JS; Franceschi E; Clement PM; Weller M; Ansell P; Looman J; Bain E; Morfouace M; Gorlia T; van den Bent M
Neuro Oncol; 2019 Oct; 21(10):1263-1272. PubMed ID: 31125418
[TBL] [Abstract][Full Text] [Related]
33. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.
Hirsch FR; Varella-Garcia M; McCoy J; West H; Xavier AC; Gumerlock P; Bunn PA; Franklin WA; Crowley J; Gandara DR;
J Clin Oncol; 2005 Oct; 23(28):6838-45. PubMed ID: 15998906
[TBL] [Abstract][Full Text] [Related]
34. Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer.
Taoudi Benchekroun M; Saintigny P; Thomas SM; El-Naggar AK; Papadimitrakopoulou V; Ren H; Lang W; Fan YH; Huang J; Feng L; Lee JJ; Kim ES; Hong WK; Johnson FM; Grandis JR; Mao L
Cancer Prev Res (Phila); 2010 Jul; 3(7):800-9. PubMed ID: 20570883
[TBL] [Abstract][Full Text] [Related]
35. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.
Hirsch FR; Varella-Garcia M; Bunn PA; Di Maria MV; Veve R; Bremmes RM; Barón AE; Zeng C; Franklin WA
J Clin Oncol; 2003 Oct; 21(20):3798-807. PubMed ID: 12953099
[TBL] [Abstract][Full Text] [Related]
36. Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.
Sartore-Bianchi A; Bencardino K; Di Nicolantonio F; Pozzi F; Funaioli C; Gambi V; Arena S; Martini M; Lamba S; Cassingena A; Schiavo R; Bardelli A; Siena S
Target Oncol; 2010 Mar; 5(1):19-28. PubMed ID: 20383783
[TBL] [Abstract][Full Text] [Related]
37. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F
J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556
[TBL] [Abstract][Full Text] [Related]
38. Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories.
Feigelson HS; Goddard KA; Johnson MA; Funk KC; Rahm AK; Kauffman TL; Chitale DA; Le Marchand L; Richards CS
BMC Res Notes; 2012 Apr; 5():196. PubMed ID: 22534075
[TBL] [Abstract][Full Text] [Related]
39. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
Woo JW; Lee K; Chung YR; Jang MH; Ahn S; Park SY
Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910
[TBL] [Abstract][Full Text] [Related]
40. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
